Xerava (eravacycline) is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older. It is effective against a broad range of susceptible microorganisms, including Gram-negative pathogens (*E. coli, K. pneumoniae*), Gram-positive pathogens (*S. aureus, Enterococcus faecalis, Enterococcus faecium*), and anaerobes (*Bacteroides* species, *Clostridium perfringens*). Xerava is not indicated for the treatment of complicated urinary tract infections (cUTI). To maintain effectiveness and reduce the development of drug-resistant bacteria, it should be reserved for infections proven or strongly suspected to be caused by susceptible bacteria.
How XERAVA Works
Eravacycline is a synthetic fluorocycline antibacterial within the tetracycline class. It exerts its bacteriostatic effect by binding to the 30S ribosomal subunit, which prevents the binding of aminoacyl-tRNA to the A-site of the ribosome. This action inhibits bacterial protein synthesis and the incorporation of amino acid residues into elongating peptide chains. Eravacycline is designed to retain activity against bacteria expressing common tetracycline resistance mechanisms, such as efflux pumps and ribosomal protection proteins.
Details
- Status
- Prescription
- First Approved
- 2018-08-27
- Patent Cliff
- 2037
- Routes
- INTRAVENOUS
- Dosage Forms
- POWDER
XERAVA Approval History
What XERAVA Treats
1 indicationsXERAVA is approved for 1 conditions since its original approval in 2018. These indications span multiple therapeutic areas including oncology, immunology, and more.
XERAVA Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to XERAVA
3 of 19FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
XERAVA FDA Label Details
Indications & Usage
FDA Label (PDF)XERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra‑abdominal infections in patients 18 years of age and older. Limitations of Use XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI). To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Complicated Intra-abdominal Infections XERAVA is indicated for the treatme...
XERAVA Patents & Exclusivity
Patents (4 active)
Exclusivity
Pro Intelligence Preview
Deep insights for XERAVA
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2037
- • 16 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 19 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.